Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6411 posts found.

Horizon Therapeutics announces real-world treatment results for Dysthyroid Optic Neuropathy drug

March 13, 2023 Medical Communications

Biopharma company Horizon Therapeutics has announced real-world treatment results for its Thyroid Eye Disease (TED) drug in patients with Dysthyroid …
News

Biotech centre focusing on gene therapies opens in Bristol, UK

March 10, 2023 Medical Communications

A new state-of-the-art facility named the Clinical Biotechnology Centre (CBC) is opening in Bristol, UK. It cost approximately £10m to …
News

FDA committee supports Roche’s lymphoma treatment

March 10, 2023 Medical Communications

 A committee at the FDA have voted in favour of Roche’s Polivy antibody drug targeting untreated diffuse large B cell …
News

Respiree gets FDA clearance for cardio-respiratory wearable

March 9, 2023 Medical Communications

Respiree, a digital therapeutics start-up, has secured the 510(k) FDA clearance for its RS001 cardio-respiratory wearable.   RS001 is a …
News

Abbott’s concussion-detecting blood test approved by FDA

March 8, 2023 Medical Communications

US-based Abbott, a medical technology company, has received FDA approval for its laboratory blood test which detects traumatic brain injury …
News

Hospital for Special Surgery reveals 3D surface topographic scan for scoliosis patients

March 8, 2023 Medical Communications

Researchers at New York City’s Hospital for Special Surgery (HSS) have found that using a 30-camera array, or 3dMD, can …
News

FDA grants de novo approval to Neuromod’s tinnitus device

March 8, 2023 Medical Communications

The FDA has granted de novo approval to Neuromod’s Lenire device which includes Bluetooth headphones, a handheld controller and the …
News

BioMarin receives FDA update for gene therapy for adults with severe haemophilia A

March 7, 2023 Medical Communications

Global biotechnology company BioMarin Pharmaceutical has announced that it’s received an update from the FDA, detailing the extension of their …
News

Sooma receives FDA Breakthrough Device designation for depression therapy device

March 7, 2023 Medical Communications

Finnish company Sooma Medical has received Breakthrough Device designation by the FDA for its portable, at-home neuromodulation device to treat …
News

Bristol Myers Squibb and Viz.ai sign multi-year partnership for HCM device

March 6, 2023 Medical Communications

Bristol Myers Squibb and Viz.ai, an AI-powered medical imaging company, have signed a deal to use AI to detect and …
News

Elon Musk’s Neuralink rejected by FDA for human trials

March 3, 2023 Medical Communications

The FDA has reportedly rejected a bid by Elon Musk’s Neuralink in which they proposed the initiation of human testing …
News

FDA grants orphan drug designation to Temferon for glioblastoma multiforme

March 3, 2023 Medical Communications

The FDA has granted Temferon an Orphan Drug Designation (ODD) for use as a therapeutic option for patients with glioblastoma …
News

A gene test could guide decisions around chemotherapy for bowel cancer

March 3, 2023 Medical Communications

Scientists from the Institute of Cancer Research London, Imperial College London and the Netherlands Cancer Institute have researched a gene …
News

Microba Life Sciences launches next-generation healthcare testing for gastrointestinal health

March 2, 2023 Medical Communications

Australian precision microbiome company Microba Life Sciences has launched its next-generation testing range for gastrointestinal health. MetaXplore has been relaunched …
News

Eli Lilly caps consumer insulin costs at $35

March 2, 2023 Medical Communications

Eli Lilly & Co has announced that it will cap out-of-pocket insulin costs at $35 per month, following a plea …
News
The Gateway to Local Adoption Series

Latest content

Sandoz launches allergy relief nasal spray in Germany and Switzerland

April 9, 2026

Japan approve Daiichi Sankyo’s Enhertu as a second-line treatment for gastric cancer

April 9, 2026

Trelleborg to take part in Medtec Japan 2026

April 8, 2026

Kainova Therapeutics expands phase I/II trial of antibody drug

April 7, 2026

Eisai starts enrolment for phase 2 narcolepsy study evaluating E2086

April 7, 2026